-
公开(公告)号：US20180134752A1
公开(公告)日：2018-05-17
申请号：US15682057
申请日：2017-08-21
Inventor： Rachel BAR-SHAVIT
CPC classification number: C07K7/08 , A61K38/08 , A61K38/10 , A61K38/177 , C07K7/06 , C07K14/705 , C07K14/723
Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
-
公开(公告)号：US20150125430A1
公开(公告)日：2015-05-07
申请号：US14534394
申请日：2014-11-06
Inventor： Dina BEN YEHUDA , Ihab Abd-Elrahman , Riki Perlman , Marjorie Pick
IPC: A61K38/17 , A61K45/06 , A61K35/14 , C12N5/078 , C12N5/0789
CPC classification number: A61K38/1761 , A61K35/28 , A61K35/545 , A61K45/06 , C12N5/0644 , C12N5/0647 , C12N2501/48 , C12N2501/727 , C12N2501/999
Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
Abstract translation: 提供诱导血小板生成和/或治疗受试者血小板减少症的方法。 因此，提供了一种方法，其包括使干细胞与由Livin衍生的血小板或造血祖细胞的分化潜能接触，从而诱导血小板生成。 还提供了一种方法，其包括使具有分化潜力的细胞与血小板与tLivin接触，从而诱导血小板生成。 还提供了用于在受试者中诱导血小板生成和/或治疗血小板减少症的组合物和分离的细胞群。
-
63.发明申请RETINAL PIGMENT EPITHELIAL CELLS DIFFERENTIATED FROM EMBRYONIC STEM CELLS WITH NICOTINAMIDE AND ACTIVIN A 审中-公开来自具有尼古丁和激活素A的胚胎干细胞分化的后皮肤上皮细胞公开(公告)号：US20150118749A1
公开(公告)日：2015-04-30
申请号：US14583848
申请日：2014-12-29
Inventor： Masha IDELSON , Ruslana ALPER-PINUS , Alex OBOLENSKY , Eyal BANIN , Benjamin Eithan REUBINOFF
CPC classification number: A61K35/30 , A61K9/0051 , A61K35/44 , A61K35/48 , C12N5/0621 , C12N5/0696 , C12N2500/38 , C12N2500/90 , C12N2500/99 , C12N2501/115 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/999 , C12N2502/13 , C12N2506/02 , C12N2533/52
Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
Abstract translation: 本发明涉及通过从干细胞，特别是人干细胞的定向分化而获得的RPE细胞。 已经具体地发现，在一种或多种TGFβb的成员的存在下培养干细胞; 超家族，如激活素A）诱导定向分化成成熟和功能性RPE细胞。 这证明了成熟RPE细胞特异性标志物的表达，包括MiTF-A，RPE65或Bestrophin）。 根据一个具体实施方案，细胞是先前用烟酰胺（NA）培养的，其被发现增加细胞对TGFβ的一种或多种成员的诱导作用的反应; 超家族 本发明还提供了进行定向分化的方法以及使用所得RPE细胞的方法。
-
64.发明授权公开(公告)号：US08980244B2
公开(公告)日：2015-03-17
申请号：US13862927
申请日：2013-04-15
Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services and Development Ltd. , Ben-Gurion University of the Negev Research and Development Authority
Inventor： Ofer Mandelboim , Angel Porgador , Yaakov Naparstek , Chamutal Gur
IPC: A61K38/17 , A61K39/395 , C07K16/28 , C07K14/705 , A61P3/10 , A61K39/00 , A61K38/00
CPC classification number: A61K39/3955 , A61K38/00 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K16/2803 , C07K16/2851 , C07K2319/30
Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Abstract translation: 本发明涉及天然细胞毒性受体NKp46用于预防和治疗糖尿病，包括I型糖尿病（TID）和2型糖尿病的用途。 特别地，本发明提供了包含NKp46细胞外区域片段的组合物，用于预防糖尿病的发病和进展。
-
65.发明申请公开(公告)号：US20150044314A1
公开(公告)日：2015-02-12
申请号：US14523408
申请日：2014-10-24
Applicant: Hadasit Medical Research Services and Development Ltd. , Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Inventor： Ruth Gabizon , Haim Ovadia , Oded Abramsky , Shlomo Magdassi , Liraz Larush
IPC: A61K9/107 , A61K45/06 , A61K31/202 , A23L1/30 , A61K47/14 , A61K47/10 , A61K47/24 , A61K47/22 , A61K36/185 , A61K47/26
CPC classification number: A61K9/107 , A23L33/115 , A61K9/1075 , A61K31/202 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/22 , A61K47/24 , A61K47/26 , A61K47/44
Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
Abstract translation: 本发明涉及石榴油及其部分用于预防和治疗神经变性疾病的用途。 特别地，本发明涉及石榴油或其部分的乳液用于预防和治疗脑疾病，包括克雅氏病（CJD）和多发性硬化症（MS）。
-
Patent Agency Ranking
公开(公告)号：US20240197914A1
公开(公告)日：2024-06-20
申请号：US18390880
申请日：2023-12-20
Applicant: Oklahoma Medical Research Foundation , Hadasit Medical Research Services and Development Ltd.
Inventor： Wan Hee Yoon , Tamar Harel
CPC classification number: A61K48/005 , A61K48/0025 , A61P43/00 , C12N9/22 , G16H20/10
Abstract: Provided herein are compositions and methods for introducing a genetic change in the genome of a cell with an exogenous DNA template-free Cas-based genome editing system comprising: (i) identifying a target genomic sequence of the genome comprising 88% or higher homology with one or more paralogs or pseudogenes that differ by one or more nucleotides; wherein the homologous region in the one or more paralogs or pseudogenes having a desired nucleotide sequence for transfer to the target genomic sequence after a double-strand break (DSB) by Cas-based genome editing; (ii) introducing into the cell a variant-specific sgRNA to cause a unidirectional transfer of genomic DNA from the homologous DNA sequences to the target genomic sequence, and (iii) contacting the genome of the cell with the variant-specific sgRNA and a Cas-based genome editing system, thereby introducing the genetic conversion without the exogenous DNA template.
-
公开(公告)号：US20240139167A1
公开(公告)日：2024-05-02
申请号：US18277257
申请日：2022-02-16
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor： Or KAKHLON , Miguel Enrique WEIL
IPC: A61K31/4436 , A61P3/00
CPC classification number: A61K31/4436 , A61P3/00
Abstract: Disclosed herein is a polypeptide including a pharmaceutical composition for use in prevention or treatment of a disease or a disorder associated with lysosomal storage and an autophagy-misregulation associated disease. Further provided are agents that bind a region of an N-terminal domain of a lysosomal-associated membrane protein 1 (LAMP-1), and methods for treating or preventing development of a disease or a disorder associated with lysosomal storage, polyglucosan accumulation or abnormal glycogen accumulation and autophagy-misregulation in a subject in need thereof.
-
公开(公告)号：US11872328B2
公开(公告)日：2024-01-16
申请号：US16643061
申请日：2018-08-28
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , AZRIELI COLLEGE OF ENGINEERING JERUSALEM
Inventor： Yoav Mintz , Nikolai Kunicher , Tali Tavor Re'em
IPC: A61F2/00 , A61L31/04 , A61K31/734 , A61K33/14
CPC classification number: A61L31/042 , A61F2/0063 , A61K31/734 , A61K33/14 , A61F2002/0072
Abstract: Disclosed herein are devices/kits and methods for reducing, treating, preventing or eliminating post-operative adhesions in an intervention/target site within a body of a subject. The method comprises the steps of: introducing an applicator, configured for applying an anti-adhesive composition, into an intervention/target site within a body of a subject; applying the anti-adhesive composition onto the intervention/target site; and extracting the applicator from the body of the subject, wherein the method is performed during or following an interventional procedure.
-
公开(公告)号：US11746324B2
公开(公告)日：2023-09-05
申请号：US17547863
申请日：2021-12-10
Inventor： Benjamin Eithan Reubinoff , Orna Singer
CPC classification number: C12N5/0621 , A61K9/0051 , A61K35/30 , A61P27/02 , C12N2500/38 , C12N2501/115 , C12N2501/15 , C12N2502/13 , C12N2506/02 , C12N2533/52 , C12N2533/54
Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGFβ superfamily.
-
公开(公告)号：US20230086868A1
公开(公告)日：2023-03-23
申请号：US18058425
申请日：2022-11-23
Inventor： Francois Binette , Gary Hogge , Rami Skaliter , Avi Ben Shabat , Jordi Monés , Eyal Banin , Tina Guanting Qiu
Abstract: Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.
-
-
-
-
-
-
-
-
-
Search Results
180
records
(took 0.023 seconds)
